DEHA is a preclinical stage pharmaceutical company founded in 2015. The company focuses on developing best-in-class therapies for the treatment of edema related disorders of unmet medical need in patients with large stroke, TBI and several other CNS injuries.
Innovative compounds targeting key driver of edema in several indications. Our discovery efforts have yielded multiple potent water channel inhibitors. These compounds have the opportunity to treat edema-related disorders. DEHA plans to move forward in its development by requesting FDA “Fast-track” development status and “Orphan” designation.